<pad> HPV2 exposure during pregnancy should be reported to the GlaxoSmithKline Pregnancy Registry at telephone (202)452-9622.• Efficacy and impact of HPV vaccine in the United States will continue to provide additional data on HPV vaccine screening activities (211,212 doses have been introduced in the United States since 2006 and evaluation of HPV vaccine safety is ongoing).• Monitoring impact of HPV vaccine in the United States will continue to provide additional data on HPV vaccine screening activities (209,212 doses have been introduced in the United States since 2006 and evaluation of HPV vaccine safety is ongoing). HPV2 exposure during pregnancy should be reported to the GlaxoSmithKline Pregnancy Registry at telephone (202)452-9622.• Efficacy and impact of HPV vaccine in the United States will continue to provide additional data on HPV vaccine screening activities (211,212 doses have been introduced in the United States since 2006 and evaluation of HPV vaccine safety is ongoing). HPV2 exposure during pregnancy should be reported to the GlaxoSmithKline Pregnancy Registry at telephone (202)452-9622.• Monitoring impact of HPV vaccine in the United States will continue to provide additional data on HPV vaccine screening activities (209,212 doses have been introduced in the United States since 2006 and evaluation of HPV vaccine safety is ongoing). HPV2 exposure during pregnancy should be reported to the GlaxoSmithKline Pregnancy Registry at telephone (202)452</s>